AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22473217 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive consultation with a 3-month follow-up
Number of subjects: 495
Study 19580467 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 2111
Study 19580467 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2111
Study 17631335 — intervention group
Group type: EXPERIMENTAL
Intervention: Open label bacillus Calmette-Guerin
Number of subjects: 156
Study 17631335 — intervention group
Group type: COMPARATOR
Intervention: Open label bacillus Calmette-Guerin (after initial placebo)
Number of subjects: 156
Study 17631335 — intervention group
Group type: COMPARATOR
Intervention: Open label bacillus Calmette-Guerin (after initial bacillus Calmette-Guerin)
Number of subjects: 156
Study 15673388 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral quinidine
Number of subjects: 5
Study 15673388 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy normal subjects)
Number of subjects: 5
Study 12045508 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterolateral fusion (Group 1)
Number of subjects: 222
Study 12045508 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterolateral fusion combined with variable screw placement (Group 2)
Number of subjects: 222
Study 12045508 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterolateral fusion combined with variable screw placement and interbody fusion (Group 3)
Number of subjects: 222
Study 12045508 — intervention group
Group type: EXPERIMENTAL
Intervention: All surgical techniques (Groups 1, 2, and 3)
Number of subjects: 222
Study 12045508 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical group
Number of subjects: 222
Study 8144735 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% metronidazole collagen device
Number of subjects: 28
Study 8144735 — intervention group
Group type: COMPARATOR
Intervention: Debridement
Number of subjects: 28
Study 3343914 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate diet (HC) - 71% carbohydrate, isonitrogenous very-low-calorie diet (VLCD) of 2,219 kJ (530 kcal).d‐1
Number of subjects: 12
Study 3343914 — intervention group
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet (LC) - 33% carbohydrate, isonitrogenous very-low-calorie diet (VLCD) of 2,219 kJ (530 kcal).d‐1
Number of subjects: 12
Study 3343914 — intervention group
Group type: COMPARATOR
Intervention: Both HC and LC groups (supervised exercise sessions at 60% peak VO2, 3 times.wk‐1 for 30 to 45 min)
Number of subjects: 12
Study 30579747 — intervention group
Group type: EXPERIMENTAL
Intervention: L-PRF
Number of subjects: 60
Study 30579747 — intervention group
Group type: EXPERIMENTAL
Intervention: L-PRF + HA
Number of subjects: 60
Study 30579747 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 27689320 — intervention group
Group type: EXPERIMENTAL
Intervention: Supramaximal sprint time trials (STT 1)
Number of subjects: 10
Study 27689320 — intervention group
Group type: EXPERIMENTAL
Intervention: Supramaximal sprint time trials (STT 4)
Number of subjects: 10
Study 26033332 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined video feedback with audience feedback (VF + AF)
Number of subjects: 41
Study 26033332 — intervention group
Group type: EXPERIMENTAL
Intervention: Video feedback only (VF)
Number of subjects: 41
Study 26033332 — intervention group
Group type: EXPERIMENTAL
Intervention: Audience feedback only (AF)
Number of subjects: 41
Study 26033332 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 41
Study 23580100 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion intervention
Number of subjects: 0
Study 21598890 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative intra-articular injection of morphine, bupivacaine with epinephrine, and ketorolac
Number of subjects: 30
Study 21598890 — intervention group
Group type: COMPARATOR
Intervention: Injectable sterile saline (control)
Number of subjects: 30
Study 19667286 — intervention group
Group type: EXPERIMENTAL
Intervention: BAL8557 (100 mg isavuconazole) intravenous administration
Number of subjects: 48
Study 19667286 — intervention group
Group type: EXPERIMENTAL
Intervention: BAL8557 (100 mg isavuconazole) oral administration
Number of subjects: 48
Study 16449476 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 159
Study 16449476 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 159
Study 16449476 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 159
Study 16449476 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation treatment (up to 1 year)
Number of subjects: 159
Study 16449476 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall antidepressant response
Number of subjects: 159
Study 16285312 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with methylaminooxopentanoate (Metvix) and a broad band light source (PhotoDyn 501)
Number of subjects: 28
Study 11182341 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiglan (1% alprostadil)
Number of subjects: 60
Study 11182341 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 60
Study 9383357 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative stabilization (OS)
Number of subjects: 133
Study 9383357 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment (NT)
Number of subjects: 133
Study 8235691 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine (FDB)
Number of subjects: 262
Study 8235691 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide/Doxorubicin/Prednisone (CAP)
Number of subjects: 262
Study 8235691 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide/Doxorubicin/Vincristine/Prednisone (CHOP)
Number of subjects: 262
Study 8235691 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide/Doxorubicin/Prednisone (CAP) in stage C CLL
Number of subjects: 262
Study 8235691 — intervention group
Group type: COMPARATOR
Intervention: Fludarabine (FDB) in stage C CLL
Number of subjects: 262
Study 8235691 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide/Doxorubicin/Vincristine/Prednisone (CHOP) in stage C CLL
Number of subjects: 262
Study 3392892 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate 2.5 mg/h
Number of subjects: 6
Study 3392892 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate 0.3 mg/kg/h
Number of subjects: 6
Study 3392892 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 6
Study 30659665 — intervention group
Group type: EXPERIMENTAL
Intervention: Euhydrated (EUH)
Number of subjects: 11
Study 30659665 — intervention group
Group type: COMPARATOR
Intervention: Hypohydrated (HYP)
Number of subjects: 11
Study 27490066 — intervention group
Group type: EXPERIMENTAL
Intervention: ASHRAE 62.2‐2010
Number of subjects: 81
Study 27490066 — intervention group
Group type: COMPARATOR
Intervention: ASHRAE 62‐1989
Number of subjects: 81
Study 27490066 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (ASHRAE 62.2‐2010 and ASHRAE 62‐1989)
Number of subjects: 81
Study 25213687 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy (routine medications replaced with study regimen to achieve blood pressure <140/90 mm Hg)
Number of subjects: 47
Study 23462943 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy/Ca (high dairy, ≈ 1400 mg/day Ca, ‐500 kcal/day)
Number of subjects: 49
Study 23462943 — intervention group
Group type: COMPARATOR
Intervention: Control (low dairy, ≈ 700 mg/day Ca, ‐500 kcal/day)
Number of subjects: 49
Study 22263599 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g white sesame seeds daily
Number of subjects: 38
Study 22263599 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified, but 240 kcal removed from diet)
Number of subjects: 38
Study 20225466 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Tri‐S Bond
Number of subjects: 4
Study 20225466 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐Bond
Number of subjects: 4
Study 20225466 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 4
Study 20225466 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Single Bond
Number of subjects: 4
Study 20225466 — intervention group
Group type: COMPARATOR
Intervention: One-step adhesives (Clearfil Tri‐S Bond and G‐Bond)
Number of subjects: 4
Study 17541495 — intervention group
Group type: EXPERIMENTAL
Intervention: Inversion of the transversalis fascia (TF) during laparoscopic inguinal hernia repair
Number of subjects: 216
Study 17541495 — intervention group
Group type: COMPARATOR
Intervention: No inversion of the transversalis fascia (TF) during laparoscopic inguinal hernia repair
Number of subjects: 216
Study 17541495 — intervention group
Group type: EXPERIMENTAL
Intervention: Inversion of the transversalis fascia (TF)
Number of subjects: 216
Study 17541495 — intervention group
Group type: COMPARATOR
Intervention: No inversion of the transversalis fascia (TF)
Number of subjects: 216
Study 15197051 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinacea purpurea (100 mg, freeze-dried pressed juice from the aerial portion of the plant) 3 times daily until symptoms relieved or 14 days
Number of subjects: 128
Study 15197051 — intervention group
Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 128
Study 11479480 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (ASA) monotherapy, n = 16
Number of subjects: 48
Study 11479480 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with ticlopidine (TIC) and ASA, n = 16
Number of subjects: 48
Study 11479480 — intervention group
Group type: COMPARATOR
Intervention: No antiplatelet drug (patient control), n = 16
Number of subjects: 48
Study 11479480 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including ASA and TIC therapy)
Number of subjects: 48
Study 9828641 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 609
Study 9828641 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional laser coagulation)
Number of subjects: 609
Study 7830324 — intervention group
Group type: EXPERIMENTAL
Intervention: Special care (therapeutic drug regimens including clonidine, nifedipine, atenolol+chlorthalidone)
Number of subjects: 655
Study 7830324 — intervention group
Group type: COMPARATOR
Intervention: Free therapy (by personal physicians without special intervention)
Number of subjects: 655
Study 7830324 — intervention group
Group type: COMPARATOR
Intervention: Normotensive subjects (control group)
Number of subjects: 655
Study 7830324 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of atenolol and chlorthalidone
Number of subjects: 655
Study 2974778 — intervention group
Group type: EXPERIMENTAL
Intervention: Group education by diabetes specialist nurses and a dietitian (5 sessions of 90 minutes each over 6 months)
Number of subjects: 75
Study 2974778 — intervention group
Group type: EXPERIMENTAL
Intervention: Group education by diabetes specialist nurses and a dietitian
Number of subjects: 75
Study 30296920 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial dry needling (SDN)
Number of subjects: 40
Study 30296920 — intervention group
Group type: COMPARATOR
Intervention: Deep dry needling (DDN)
Number of subjects: 40
Study 30296920 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure pain threshold (PPT) measurements
Number of subjects: 40
Study 30296920 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analog scale scores
Number of subjects: 40
Study 30296920 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal jaw opening
Number of subjects: 40
Study 29579320 — intervention group
Group type: EXPERIMENTAL
Intervention: Platysma muscle suture
Number of subjects: 82
Study 29579320 — intervention group
Group type: COMPARATOR
Intervention: No platysma muscle suture
Number of subjects: 82
Study 29579320 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 82
Study 28439597 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambu AuraOnce
Number of subjects: 112
Study 28439597 — intervention group
Group type: COMPARATOR
Intervention: i-gel
Number of subjects: 112
Study 25617119 — intervention group
Group type: EXPERIMENTAL
Intervention: Novasial (oral saliva equivalent) administered four times daily
Number of subjects: 0
Study 25617119 — intervention group
Group type: COMPARATOR
Intervention: Aequasyal (oxygenated glycerol triester oral spray)
Number of subjects: 0
Study 25617119 — intervention group
Group type: COMPARATOR
Intervention: Biotene (moisturizing spray)
Number of subjects: 0
Study 25617119 — intervention group
Group type: EXPERIMENTAL
Intervention: Novasial
Number of subjects: 0
Study 24066182 — intervention group
Group type: EXPERIMENTAL
Intervention: Open Reduction and Internal Fixation (ORIF)
Number of subjects: 130
Study 24066182 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 130
Study 21336679 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy-based weight management program (n=44)
Number of subjects: 68
Study 21336679 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=24)
Number of subjects: 68
Study 18297435 — intervention group
Group type: EXPERIMENTAL
Intervention: Pan-colonic NBI system
Number of subjects: 243
Study 18297435 — intervention group
Group type: COMPARATOR
Intervention: Conventional colonoscopy
Number of subjects: 243
Study 16553016 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.3 mg
Number of subjects: 25
Study 16553016 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 120 mg
Number of subjects: 25
Study 16553016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 14585211 — intervention group
Group type: EXPERIMENTAL
Intervention: bivalent HIV gp120 SF2/CM235 vaccine
Number of subjects: 12
Study 10938185 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroquinidine (450 mg/day)
Number of subjects: 10
Study 10938185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8751695 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection at 4 ml/sec with a 25-sec scan delay
Number of subjects: 217
Study 8751695 — intervention group
Group type: COMPARATOR
Intervention: Injection at 4 ml/sec with a 20-sec scan delay
Number of subjects: 217
Study 8751695 — intervention group
Group type: COMPARATOR
Intervention: Injection at 2 ml/sec with a 30-sec scan delay
Number of subjects: 217
Study 8751695 — intervention group
Group type: COMPARATOR
Intervention: Injection at 2 ml/sec with a 35-sec scan delay
Number of subjects: 217
Study 8751695 — intervention group
Group type: COMPARATOR
Intervention: Injection at 2 ml/sec
Number of subjects: 217
Study 8751695 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection at 4 ml/sec
Number of subjects: 217
Study 8751695 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial-phase helical CT
Number of subjects: 217
Study 8751695 — intervention group
Group type: COMPARATOR
Intervention: Portal-venous phase helical CT
Number of subjects: 217
Study 1574965 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (r-HuEPO) at a dose of 100 U/kg given intravenously twice weekly for 6 weeks
Number of subjects: 0
Study 1574965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2410117 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP) 32 mg daily for 14 days
Number of subjects: 40
Study 2410117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 2410117 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP)
Number of subjects: 40
Study 31269914 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT) for 8 weeks, 3 times weekly, with an average of 78 ± 5.1 minutes of exercise completed out of 90 minutes.
Number of subjects: 30
Study 31269914 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control group (CON)
Number of subjects: 30
Study 29703226 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised Modular Treatment Programme (IMTP) - 10 sessions of individual cognitive behavioural therapy with adolescents and/or parents, focusing on three out of ten available modules.
Number of subjects: 160
Study 29703226 — intervention group
Group type: COMPARATOR
Intervention: Telephone-assisted self-help programme for parents (TASH) - combines bibliotherapeutic components with 10 counselling sessions for parents via telephone.
Number of subjects: 160
Study 27164293 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose exercise (16 kcal/kg of weight/week)
Number of subjects: 122
Study 27164293 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose exercise (4 kcal/kg of weight/week)
Number of subjects: 122
Study 27164293 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 122
Study 24659192 — intervention group
Group type: EXPERIMENTAL
Intervention: Probability training
Number of subjects: 0
Study 24659192 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaming
Number of subjects: 0
Study 24659192 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracking (top 2% from Year 1 in elite teams)
Number of subjects: 0
Study 24659192 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical algorithms (reported elsewhere)
Number of subjects: 0
Study 22153001 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional inactivated poliovirus vaccine (IPV) administered intradermally (ID)
Number of subjects: 100
Study 22153001 — intervention group
Group type: COMPARATOR
Intervention: Full dose inactivated poliovirus vaccine (IPV) administered intramuscularly (IM)
Number of subjects: 100
Study 22153001 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional IPV dose administered by ID route
Number of subjects: 100
Study 22153001 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of IPV
Number of subjects: 100
Study 22153001 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events monitoring
Number of subjects: 100
Study 20499357 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-yearly i.v. infusion of ZOL 5 mg
Number of subjects: 302
Study 20499357 — intervention group
Group type: COMPARATOR
Intervention: Once-weekly oral ALN 70 mg
Number of subjects: 302
Study 17539899 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic test scenario (high-risk result)
Number of subjects: 261
Study 17539899 — intervention group
Group type: COMPARATOR
Intervention: Oxidative test scenario (high-risk result)
Number of subjects: 261
Study 15186610 — intervention group
Group type: EXPERIMENTAL
Intervention: TRIAC 0.03%
Number of subjects: 18
Study 15186610 — intervention group
Group type: EXPERIMENTAL
Intervention: TRIAC 0.1%
Number of subjects: 18
Study 15186610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 11441544 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicryl Rapide suture (n = 61)
Number of subjects: 101
Study 11441544 — intervention group
Group type: COMPARATOR
Intervention: 3‐0 Supramid suture (n = 40)
Number of subjects: 101
Study 9850068 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg twice a day) plus rhEPO (12,000-30,000 units per week)
Number of subjects: 108
Study 9850068 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (50 mg twice a day)
Number of subjects: 108
Study 7851281 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.15‐0.9 mg/day)
Number of subjects: 39
Study 7851281 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.3‐0.9 mg/day)
Number of subjects: 39
Study 7851281 — intervention group
Group type: EXPERIMENTAL
Intervention: Lefetamine (60‐240 mg/day)
Number of subjects: 39
Study 2670659 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate suspension, 4 g/day (10 ml four times a day)
Number of subjects: 19
Study 2670659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 2670659 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate suspension
Number of subjects: 19
Study 73797 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 1.6 g daily
Number of subjects: 47
Study 73797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 73797 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 0.8 g daily
Number of subjects: 47
Study 31008633 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 87
Study 31008633 — intervention group
Group type: COMPARATOR
Intervention: Wait list
Number of subjects: 87
Study 27859629 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Escherichia coli lipopolysaccharide (LPS)
Number of subjects: 15
Study 27859629 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial Escherichia coli lipopolysaccharide (LPS)
Number of subjects: 15
Study 26118427 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisporivir (ALV) 1,000 mg once-daily (QD)
Number of subjects: 340
Study 26118427 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisporivir (ALV) 600 mg QD and ribavirin (RBV)
Number of subjects: 340
Study 26118427 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisporivir (ALV) 800 mg QD and ribavirin (RBV)
Number of subjects: 340
Study 26118427 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisporivir (ALV) 600 mg QD and pegylated interferon (Peg-IFN)
Number of subjects: 340
Study 26118427 — intervention group
Group type: COMPARATOR
Intervention: Pegylated interferon (Peg-IFN) and ribavirin (RBV)
Number of subjects: 340
Study 26118427 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisporivir (ALV) and ribavirin (RBV) after rapid virological response (RVR)
Number of subjects: 340
Study 26118427 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisporivir (ALV) alone after rapid virological response (RVR)
Number of subjects: 340
Study 26118427 — intervention group
Group type: COMPARATOR
Intervention: Pegylated interferon (Peg-IFN) and ribavirin (RBV) after rapid virological response (RVR)
Number of subjects: 340
Study 23547804 — intervention group
Group type: EXPERIMENTAL
Intervention: High Osteoprotegerin (OPG) levels
Number of subjects: 206
Study 23547804 — intervention group
Group type: EXPERIMENTAL
Intervention: Unadjusted survival analysis of OPG
Number of subjects: 206
Study 23547804 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted analyses of OPG
Number of subjects: 206
Study 21596740 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery with disc prosthesis
Number of subjects: 173
Study 21596740 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation
Number of subjects: 173